Login to Your Account



As Heart Drug Fails Again In Women

Rotarix Approved In Europe; Avant Due $40M At Launch

By Randall Osborne


Tuesday, February 28, 2006
Avant Immunotherapeutics Inc. said GlaxoSmithKline plc, its worldwide partner for commercializing the Rotarix vaccine, won approval in the European Union for preventing gastroenteritis caused by rotavirus in children, and Avant is due $40 million when the drug is launched. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription